Kindstar Globalgene Technology (Kindstar Globalgene Technology) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology Debt-to-Equity?

Kindstar Globalgene Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $23.1 Mil. Kindstar Globalgene Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.1 Mil. Kindstar Globalgene Technology's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $402.2 Mil. Kindstar Globalgene Technology's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kindstar Globalgene Technology's Debt-to-Equity or its related term are showing as below:

KDGTF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.45 Med: -0.02 Max: 0.07
Current: 0.07

During the past 6 years, the highest Debt-to-Equity Ratio of Kindstar Globalgene Technology was 0.07. The lowest was -0.45. And the median was -0.02.

KDGTF's Debt-to-Equity is ranked better than
78.24% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs KDGTF: 0.07

Kindstar Globalgene Technology Debt-to-Equity Historical Data

The historical data trend for Kindstar Globalgene Technology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology Debt-to-Equity Chart

Kindstar Globalgene Technology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.39

-0.05

0.01

0.07

Kindstar Globalgene Technology Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					0.01	0.01	0.07	0.08	0.07

Competitive Comparison of Kindstar Globalgene Technology's Debt-to-Equity

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kindstar Globalgene Technology's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's Debt-to-Equity falls into.

Kindstar Globalgene Technology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kindstar Globalgene Technology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(23.113	+	4.097)	/	402.229
	=	0.07

Kindstar Globalgene Technology's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(23.113	+	4.097)	/	402.229
	=	0.07

Kindstar Globalgene Technology (OTCPK:KDGTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kindstar Globalgene Technology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindstar Globalgene Technology (Kindstar Globalgene Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (OTCPK:KDGTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

09960:Hong Kong

Address

Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN

Website

https://www.kindstar.com.cn

Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services. It organizes the business into nine segments, including hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, and Other segment provides Testing services for R&D projects and others and miscellaneous services.

Kindstar Globalgene Technology (Kindstar Globalgene Technology) Headlines

No Headlines